FRANKFURT (Reuters) – Bayer said on Monday it acquired the exclusive marketing rights for Europe for a new drug that is under regulatory review to treat a rare, potentially fatal heart disease for up to $310 million upfront.
The German drugmaker said it struck the deal with Eidos Therapeutics Inc., BridgeBio International GmbH and BridgeBio Europe B.V.
The drug acoramidis is under review to treat a progressive hear disease known as ATTR CM.
(Reporting by Ludwig Burger, Editing by Rachel More)
Comments